Description:BGT226, with the CAS number 1245537-68-1, is a chemical compound that has garnered attention in the field of medicinal chemistry, particularly for its potential therapeutic applications. It is classified as a small molecule inhibitor, specifically targeting certain pathways involved in cellular signaling and proliferation. BGT226 is known to inhibit the activity of phosphoinositide 3-kinase (PI3K) and mammalian target of rapamycin (mTOR), which are crucial in regulating cell growth, survival, and metabolism. This inhibition can lead to the suppression of tumor growth, making it a candidate for cancer treatment. The compound is typically characterized by its specific molecular structure, which includes various functional groups that contribute to its biological activity. Additionally, BGT226 has been studied for its pharmacokinetic properties, including absorption, distribution, metabolism, and excretion (ADME), which are essential for understanding its efficacy and safety profile in clinical settings. As research continues, further insights into its mechanism of action and potential side effects are being explored.
Synonyms:
BGT-226 maleate
1-(3-(Trifluoromethyl)-4-(piperazin-1-yl)phenyl)-8-(6-methoxypyridin-3-yl)-3-methyl-1H-imidazo[4,5-c]quinolin-2(3H)-one maleic acid salt
We use cookies to enhance your visit. We do not include advertising.
Please see our Cookies Policy for more details or adjust your preferences in "Settings".
This is the advanced settings system for our own and third-party cookies. Here you can modify parameters that will directly affect your browsing experience on this website. If you wish you may check the list of Cookie types.
Please note that disabling cookies can cause failures in the normal operation of the web.
